Displaying drugs 10351 - 10375 of 10489 in total
Tariquidar
Investigational
Bioymifi
Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic. Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.[A257048,A257053]
Investigational
Actelion-1
Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.
Investigational
Human Amniotic Fluid
Human amniotic fluid is the liquid surrounding the human embryo and fetus. Physically, the fluid provides protection through cushioning. Chemically, the fluid provides protection through its inherent antibacterial properties. The fluid contains carbohydrates, proteins, lipids, electrolytes, urea, immunoglobulins, growth factors, and vitamins.[L16373,L16378]
Investigational
Talactoferrin alfa
Talactoferrin alfa is a novel immunomodulatory 80 kD protein with demonstrated oral anti-tumor properties. Lactoferrin, a protein found in breast milk is developed by Agennix. It increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation.
Investigational
AMG-222
Investigational
Descartes-30
Descartes-30 is an RNA-engineered off-the-shelf allogeneic mesenchymal stem cell (MSC) product developed by Cartesian Therapeutics. The RNA-engineering is performed with Cartesian Therapeutics’ proprietary RNA Armory which is a platform that activates and provides cells with mRNA-based therapeutics.
Investigational
INGN 201
INGN 201(Advexin) is a replication-impaired adenoviral vector that carries the p53 gene, has been evaluated in both preclinical and clinical trials. Advexin is a well-tolerated and efficacious treatment for numerous cancers, both as monotherapy and in combination with radiation and/or chemotherapy agents.
Investigational
Talmapimod
Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.
Investigational
Lactobacillus coryniformis K8
Lactobacillus is a common bacteria found in the gut with Lactobacillus coryniformis K8 being originally isolated from artisan goat cheese.
Investigational
Lestaurtinib
Investigational
Xaliproden
Investigational
XL228
XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation, survival and metastasis.
Investigational
Arylacenamide
Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2. It is a dual agent with both immunomodulatory and antiproliferative activities.
Investigational
NPS-2143
Investigational
Fx-1006A
Fx-1006A is a small molecule compound with the potential to treat genetic disorders, such as familial amyloid cardiomyopathy (FAC) and familial amyloid polyneuropathy (FAP).
Investigational
Plinabulin
Investigational
Abafungin
Investigational
ATL-2502
ATL-2502(Colal-Pred) is an old drug (prednisolone metasulphobenzoate, a steroid) with a new delivery system that releases the medication only in the colon. Releasing the drug directly into the colon reduces the potential for significant side effects often experienced with steroid drugs. Colal-Pred is being studied for use in ulcerative colitis.
Investigational
NV-07a
NV-07a is topical skin repair compound protecting skin from sun-induced immunosuppression and UV-induced damage.
Investigational
Onercept
Investigational
Canertinib
Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.
Investigational
Displaying drugs 10351 - 10375 of 10489 in total